Eisai, Biogen Say FDA Extends Review Of LEQEMBI IQLIK As A Starting Dose For Early AD

The FDA extended its review of LEQEMBI IQLIK as a starting dose for early Alzheimer's disease by three months. The delay is a modest regulatory setback for Eisai and Biogen, but it does not indicate rejection. The news is likely to weigh mildly on sentiment for the stocks rather than materially alter the broader sector.

Analysis

The FDA extended its review of LEQEMBI IQLIK as a starting dose for early Alzheimer's disease by three months. The delay is a modest regulatory setback for Eisai and Biogen, but it does not indicate rejection. The news is likely to weigh mildly on sentiment for the stocks rather than materially alter the broader sector.